Explore UAB
Biomedical Informatics and Data Science • November 18, 2026

The UAB Systems Pharmacology AI Research Center (SPARC), in collaboration with Southern Research, has announced the three winning teams of the 2026 SPARC Drug Discovery CollaboFest, an initiative designed to transform promising biomedical research ideas into experimentally testable therapeutic strategies through artificial intelligence, computational drug discovery, and laboratory validation.

The inaugural competition attracted eight multidisciplinary teams, with three selected following a competitive evaluation by a panel of five expert judges. The winning proposals represent innovative approaches to ovarian cancer treatment, antiviral therapeutics, and AI-driven drug discovery for gout and pseudogout.

Meet the three winning teams

James Kobie, Ph.D. — professor, UAB Department of Medicine, Division of Infectious Diseases

Project: Therapeutic Antibody Development for Inhibin A and HE4 in Ovarian Cancer

Led by Kobie, alongside Mythreye Karthikeyan, Ph.D., associate professor in the UAB Department of Pathology; Mark Walter, Ph.D., professor in the UAB Department of Microbiology; Alexander Rosenberg, Ph.D., professor in the Department of Biomedical Informatics and Data Science; and Abhishek Rathore, Ph.D., UAB postdoctoral scholar, the team proposes developing therapeutic antibodies targeting Inhibin A and HE4 in ovarian cancer. The project aims to explore new antibody-based treatment strategies and advance promising therapeutic concepts toward experimental evaluation.


Giulia Monticone, Ph.D. — assistant professor, Louisiana State University Health Sciences Center in New Orleans

Project: Developing First-in-Class Bispecific Immuno-Antivirals

Monticone and her team propose developing a new class of bispecific immuno-antiviral therapeutics. The project seeks to advance innovative antiviral treatment approaches by moving promising biologic concepts toward therapeutic development and experimental validation.


Tony Merriman, Ph.D. — professor, UAB Department of Medicine, Division of Immunology and Rheumatology

Project: Utilization of AI Tools and Modeling to Perform Virtual Docking and Screening on Therapeutic Target Protein Structures Informed by GWAS Analysis for Gout and Pseudogout

Led by Merriman in collaboration with John Tillotson, Ph.D., scientist 2 at Southern Research, this project focuses on applying artificial intelligence, molecular modeling and virtual screening to investigate potential therapeutic targets for gout and pseudogout. Using protein structures informed by genome-wide association studies (GWAS), the team aims to identify and prioritize promising candidates for further drug discovery research.

A partnership connecting AI innovation with laboratory research

Each winning team will receive a jointly developed research support package valued at up to $40,000 in combined, in-kind services from SPARC and Southern Research, along with $1,000 in prize money provided through the Marnix E. Heersink Institute for Biomedical Innovation.

Under the collaboration, SPARC will provide AI-driven drug design, computational analysis, and systems pharmacology expertise, while Southern Research will contribute specialized wet-laboratory services to support experimental validation. Together, the organizations aim to bridge the gap between computational discoveries and practical therapeutic development.
The proposals were evaluated based on drug discovery readiness, scientific and technical merit, intellectual property and external funding potential, and investment value to the program. Although AI-assisted reviews provided preliminary assessments, the final selections were determined by expert judges through discussion and voting.

Advancing promising discoveries toward therapeutic development

The winning teams will work closely with SPARC and Southern Research to develop detailed research plans, milestones, and deliverables. SPARC's computational and AI-focused research activities are scheduled for completion in late 2026, followed by Southern Research's laboratory work during the first quarter of 2027.

The CollaboFest initiative brings together the Department of Biomedical Informatics and Data Science, the UAB-led Center for Clinical and Translational Science, the Marnix E. Heersink Institute for Biomedical Innovation, and Southern Research.

Through this multidisciplinary partnership, CollaboFest seeks to accelerate early-stage drug discovery, generate preliminary evidence for future grant applications and
publications, and create opportunities for intellectual property development and continued therapeutic innovation.

The winning teams have also been invited to present their research during the SPARC PowerTalk webinar on Nov. 13, 2026, and participate in a special CollaboFest session at the 2027 Annual Translational and Transformative Informatics Symposium.

For more information, visit the 2026 SPARC Drug Discovery CollaboFest website.


Subscribe to Heersink
School of Medicine News

Subscribe to Heersink School of Medicine News